Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung Carcinomas
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is a prospective one-arm, two-stage phase 2 trial of TVB-2640 in KRAS mutant NSCLC
patients. 13 patients will be treated with a minimum of 1 cycle of TVB-2640 therapy over 8
weeks.
Phase:
Phase 2
Details
Lead Sponsor:
David E Gerber University of Texas Southwestern Medical Center
Collaborators:
Cancer Prevention Research Institute of Texas Sagimet Biosciences Inc.